Information from an ongoing Phase 1/2 medical trial evaluating three dosage levels of Pfizer (NYSE: PFE) and collaboration partner BioNTech SEs (NASDAQ: BNTX) COVID-19 vaccine prospect BNT162b1 in healthy volunteers showed an appropriate safety profile and dose-dependent boosts in glycoprotein receptor-binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. The data, just published in the journal Nature, was produced on the first 2 dose levels, 10 µg and 30 µg. When due to increased reactogenicity and the absence of a significant incremental immunogenicity effect compared to the 30 µg dosage, the greatest dose of 100 µg was just administered.
1.6-fold to 4.6-fold increases on geometric mean reducing the effects of antibody titers after the second dosage were observed.
The business initially reported initial data from the trial on July 1. The greatest reducing the effects of titers reported then were 1.8 x (10 µg) and 2.8 x (30 µg).
Premarket: PFE up a portion, BNTX up 4%.